Patent · US Active

Assay methods for the determination of FKBPL expression level in the context of breast cancer

US9110063B2 · kind B2 · utility

0Cited by
0References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 19, 2010
Grant dateAug 18, 2015
Priority date
Expiry dateMay 30, 2030

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/99
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

Disclosed are methods that employ FKBPL as a marker for a subject's sensitivity to endocrine therapies in the treatment of cancers, and as a predictive marker of cancer progression and disease free survival in relation to hormone responsive cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.